EMA Authorised: Ristaben (sitagliptin) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA authorised Ristaben, a sitagliptin product by Merck Sharp & Dohme B.V., for treatment of type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Ristaben (sitagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Merck Sharp & Dohme B.V.. Decision date: 30/10/2025